ImmunoKey
John Bridgeman is a seasoned scientist with extensive experience in cell therapy research and immunology. Currently serving as the Chief Scientific Officer at ImmunoKey since March 2025, Bridgeman previously held the position of Director of Cell Therapy Research at Instil Bio from May 2014 to October 2024, as well as at Immetacyte Ltd. and Cellular Therapeutics Ltd. during overlapping periods in 2014-2019 and 2014-2020, respectively. Earlier, Bridgeman worked as a Research Fellow at Cardiff University from April 2010 to June 2014, where significant contributions included developing assays for viral-specific T cell receptors and establishing lentiviral transfer technologies for T-cell modulation.
This person is not in any teams
This person is not in any offices
ImmunoKey
ImmunoKey is pioneering next-generation CAR T-cell therapies to overcome the challenges of successfully treating solid tumours. https://www.immunokey.co.uk/